NRX Pharmaceuticals Inc (NRXP)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at NRX Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.20 $ — 52% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% –
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
NeutralGeprüft am 13.07.2026 gegen die Geschäftsberichte (10-K) für die Geschäftsjahre 2025 (eingereicht 23.03.2026) und 2024 (14.03.2025) sowie die vier jüngsten Quartalsberichte (10-Q, zuletzt zum 31.03.2026). NRx Pharmaceuticals ist ein klinisch-orientiertes Psychiatrie-Biotech (Wirkstoffe NRX-100 und NRX-101 gegen suizidale Depression, generisches Ketamin KETAFREE) mit der Kliniktochter HOPE Therapeutics. In den ausgewerteten SEC-Filings findet sich kein wesentlicher KI-Bezug fürs eigene Geschäftsmodell: keine KI-Produkte oder -Dienste als Umsatzquelle (Produktumsatz gibt es bislang gar keinen; der erste Umsatz stammt aus den psychiatrischen Kliniken), kein dokumentierter operativer KI-Einsatz in der Wirkstoff-Forschung und kein konkretes KI-Geschäftsrisiko in den Risk Factors. Die einzige Erwähnung von „artificial intelligence“ im 10-K 2025 steht in der Lebenslauf-Biografie des im Januar 2026 berufenen Betriebschefs Joseph Casper (frühere Aufsichtsrats- und Strategie-Rollen bei KI-Firmen wie Ryte AI und Ingine) — das ist ein persönlicher Werdegang, keine Aussage über NRx-Produkte, -Prozesse oder -Risiken. Auch die für den NRX-100-Zulassungsantrag genutzte Real-World-Evidence-Auswertung (Partner Osmind, rund 65.000 Ketamin-Patienten) beschreibt das Unternehmen als statistische Datenanalyse, nicht als KI oder maschinelles Lernen. Nach dem Kriterienkatalog (Vorrang: verkauft > bedroht > nutzt > neutral) bleibt es beim dokumentierten Negativ-Befund „neutral“.
View the full file — quotes, sources, reviewed filings
„Between March 2023 and August 2025, Mr. Casper served as the Chief Strategy Officer of Ryte AI, artificial intelligence-powered healthcare data analytics platform."
Zwischen März 2023 und August 2025 war Herr Casper Chief Strategy Officer von Ryte AI, einer KI-gestützten Plattform für Gesundheitsdatenanalyse.
„Accordingly, the Company contracted with Osmind, Inc. to analyze and submit RWE drawn from 65,000 patients treated for depression with intravenous ketamine compared to 6,000 patients treated with intranasal S-ketamine."
Entsprechend beauftragte das Unternehmen Osmind, Inc. damit, Real-World-Evidenz von 65.000 mit intravenösem Ketamin gegen Depression behandelten Patienten im Vergleich zu 6.000 mit intranasalem S-Ketamin behandelten Patienten auszuwerten und einzureichen.
Filings Reviewed: 10-K 2026-03-23 · 10-K 2025-03-14 · 10-Q 2026-05-15 · 10-Q 2025-11-14 · 10-Q 2025-08-18 · 10-Q 2025-05-15
Rated on July 13, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 1,212.5% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.09 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.21 | – | 0 | -50.00 | -226,950.00 | -2 | -2 |
| 2025: Q1 | -0.13 | – | 0 | -50.00 | -137,800.00 | -4 | -4 |
| 2025: Q2 | -0.41 | – | 0 | – | – | -4 | -4 |
| 2025: Q3 | -0.14 | – | 0 | – | -2,433.90 | -3 | -3 |
| 2025: Q4 | 0.01 | – | 1 | 24,475.00 | 36.60 | -4 | -4 |
| 2026: Q1 | -0.03 | – | 1 | 26,600.00 | -133.90 | -4 | -4 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
NRx Pharmaceuticals, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt Therapeutika zur Behandlung von Erkrankungen des zentralen Nervensystems, darunter suizidale Depression, posttraumatische Belastungsstörung (PTBS) und Schizophrenie in den USA.
| Employees | 29 |
|---|---|
| Headquarters | Wilmington, DE |
| Website | nrxpharma.com |
| IPO Date | 4. Dec 2017 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chairman & CEO | 1957 |
| Michael S. Abrams M.B.A. | CFO & Treasurer | 1970 |
| Joseph M. Casper | Chief Operating Officer | 1951 |
| Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 1962 |
| Hervé Perron HDR, Ph.D. | Chief Scientist | 1959 |
| Suzanne Messere | Investor Relations | – |
| Philip T. Lavin Ph.D. | Chief Methodologist | 1947 |
| Dennis K. McBride Ph.D. | Chief Strategy Officer & Director | 1955 |
| Prof. Joshua C. Brown M.D., Ph.D. | Chief Medical Innovation Officer | – |
| Glenn Tyson | Chief Commercial Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.